0000000000701730

AUTHOR

Dana Elias

showing 2 related works from this author

Autoimmune Diabetes Induced by the β-cell Toxin STZ: Immunity to the 60-kDa Heat Shock Protein and to Insulin

1994

Administered at a suitably low dose, the toxin streptozotocin (STZ) can trigger an autoimmune process leading to destruction of the beta-cells of the pancreatic islets. In this study, we examined specific immunological reactions in mice before and during the development of STZ-induced autoimmune diabetes. We now report that the development of spontaneous autoantibodies to insulin can serve as a marker of susceptibility to a low dose of STZ. Susceptible male mice of the C57BL/KsJ strain manifested such anti-insulin antibodies, and resistant female mice did not. Administration of a low dose of STZ (five daily doses each of 30 mg/kg) induced transient hyperglycemia approximately 20-30 days lat…

Blood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBiologyActive immunizationmedicine.disease_causeStreptozocinAutoimmune DiseasesDiabetes Mellitus ExperimentalAutoimmunityMiceInternal medicineDiabetes mellitusInternal MedicinemedicineAnimalsInsulinHeat-Shock ProteinsAutoantibodiesAutoimmune diseaseMice Inbred BALB CPancreatic isletsInsulinnutritional and metabolic diseasesmedicine.diseaseStreptozotocinMice Inbred C57BLEndocrinologymedicine.anatomical_structureFemaleImmunizationBeta cellmedicine.drugDiabetes
researchProduct

Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial.

2014

OBJECTIVE To evaluate safety and efficacy of DiaPep277 in preserving β-cell function in type 1 diabetic patients. RESEARCH DESIGN AND METHODS DIA-AID 1 is a multinational, phase 3, balanced-randomized, double-blind, placebo-controlled, parallel-group clinical study. Newly diagnosed patients (N = 457, aged 16–45 years) were randomized to subcutaneous injections of DiaPep277 or placebo quarterly for 2 years. The primary efficacy end point was the change from baseline in the area under the glucagon-stimulated C-peptide curve. Secondary end points were the change from baseline in mixed-meal stimulated C-peptide secretion and in fasting C-peptide and achieving target HbA1c ≤7% (≤53 mmol/mol). P…

Advanced and Specialized NursingResearch designType 1 diabetesmedicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismInsulinmedicine.medical_treatmentPlacebomedicine.diseaseGastroenterologySurgeryDouble blindType 1 diabetesInternal medicineDiabetes mellitusInternal MedicinemedicineRecent onsetbusinessGlycemic
researchProduct